Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects

Authors

Albert LoBuglio, University Of Alabama At Birmingham, USA
Mansoor Saleh, Aga Khan UniversityFollow
Jeannette Lee, University of Alabama at Birmingham, USA
M B. Khazaeli, University of Alabama at Birmingham, USA
Richard Carrano, Centocor, Inc. PA
Howard Holden, Centocor, Inc. PA

Document Type

Article

Department

Haematology and Oncology, East Africa

Abstract

Twenty-five patients with metastatic gastrointestinal adenocarcinoma received one to four infusions (400 mg) of murine monoclonal antibody CO17-1A. Eleven patients had mild gastrointestinal symptoms, and one had a transient flushing episode. Two of five who received three weekly infusions had readily reversible anaphylactic reactions at the time of the third infusion (day 15). There were no other toxic effects. One patient had a complete remission and is surviving at >104 weeks, and four had stable disease. The median survival for the whole group was 57 weeks. In general, the antibody infusions were well tolerated but had modest antitumor effects.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Journal of the National Cancer Institute

DOI

https://doi.org/10.1093/jnci/80.12.932

Recommended Citation

LoBuglio, A., Saleh, M., Lee, J., Khazaeli, M. B., Carrano, R., Holden, H. (1988). Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects. Journal of the National Cancer Institute, 80(12), 932-936.
Available at: https://ecommons.aku.edu/eastafrica_fhs_mc_haematol_oncol/147